We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+9.27%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+879.75%
AUM
$49B
AUM Growth
+$3.11B
(+6.8%)
Cap. Flow
+$228M
Cap. Flow
% of AUM
0.47%
Top 10 Holdings %
Top 10 Hldgs %
21.37%
Holding
1,104
New
303
Increased
294
Reduced
324
Closed
153
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$282M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$205M |
| 3 |
ConocoPhillips
COP
|
+$203M |
| 4 |
Fortive
FTV
|
+$200M |
| 5 |
Merck
MRK
|
+$178M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$665M |
| 2 |
ExxonMobil
XOM
|
+$332M |
| 3 |
Burlington
BURL
|
+$242M |
| 4 |
National Vision
EYE
|
+$186M |
| 5 |
CXO
CONCHO RESOURCES INC.
CXO
|
+$175M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.67% |
| 2 | Healthcare | 17.99% |
| 3 | Financials | 14.03% |
| 4 | Consumer Discretionary | 11.97% |
| 5 | Communication Services | 8.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Monster Beverage
MNST
$92.1B
| $37.4M | 0.08% |
821,922
+1,200
| +0.1% | +$53.8K |
|
277
Global Payments
GPN
$24B
| $37.4M | 0.08% |
185,544
-88,498
| -32% | -$17.6M |
|
278
Penumbra
PEN
$12.8B
| $37.2M | 0.08% |
+137,500
| New | +$35.5M |
|
279
Corning
GLW
$135B
| $37.1M | 0.08% |
851,621
+72,100
| +9% | +$2.77M |
|
|
SRNGU
280
DELISTED
Soaring Eagle Acquisition Corp. Unit
SRNGU
| $36.9M | 0.08% |
+3,650,000
| New | +$38M |
|
281
Extra Space Storage
EXR
$31.6B
| $36.9M | 0.08% |
278,600
+138,600
| +99% | +$16.8M |
|
282
Hilton Worldwide
HLT
$72.5B
| $36.9M | 0.08% |
305,100
+700
| +0.2% | +$80.9K |
|
283
Zimmer Biomet
ZBH
$18.8B
| $36.9M | 0.08% |
237,355
+73,439
| +45% | +$11.4M |
|
284
American International
AIG
$42.4B
| $36.9M | 0.08% |
798,221
+31,900
| +4% | +$1.38M |
|
|
ISBC
285
DELISTED
Investors Bancorp, Inc.
ISBC
| $36.7M | 0.08% |
2,501,222
+256,606
| +11% | +$3.32M |
|
286
Motorola Solutions
MSI
$78.7B
| $36.7M | 0.08% |
195,248
+4,000
| +2% | +$714K |
|
|
IMGN
287
DELISTED
Immunogen Inc
IMGN
| $36.5M | 0.07% |
4,500,000
+2,025,000
| +82% | +$16.5M |
|
288
Yum! Brands
YUM
$41.6B
| $36.3M | 0.07% |
335,461
+13,070
| +4% | +$1.38M |
|
289
Cytokinetics
CYTK
$11B
| $36.1M | 0.07% |
+1,550,000
| New | +$33.1M |
|
290
Kinder Morgan
KMI
$69.7B
| $35.9M | 0.07% |
2,157,354
+2,109,500
| +4,408% | +$32.2M |
|
291
PACCAR
PCAR
$69.5B
| $35.7M | 0.07% |
575,966
+72,344
| +14% | +$4.52M |
|
292
PNC Financial Services
PNC
$101B
| $35.3M | 0.07% |
+201,468
| New | +$33.2M |
|
293
Cleveland-Cliffs
CLF
$6.98B
| $35.2M | 0.07% |
+1,750,000
| New | +$28.5M |
|
294
Archer Daniels Midland
ADM
$37.4B
| $35.1M | 0.07% |
616,392
+1,500
| +0.2% | +$82.3K |
|
295
TransDigm Group
TDG
$69.8B
| $35M | 0.07% |
59,449
+574
| +1% | +$338K |
|
296
Labcorp
LH
$25.6B
| $34.9M | 0.07% |
159,235
+36,433
| +30% | +$7.31M |
|
297
Delta Air Lines
DAL
$60.5B
| $34.8M | 0.07% |
721,211
+24,300
| +3% | +$1.08M |
|
298
International Paper
IP
$21.5B
| $34.8M | 0.07% |
679,739
+299,425
| +79% | +$14.6M |
|
299
Avantor
AVTR
$8.91B
| $34.7M | 0.07% |
1,200,000
-150,000
| -11% | -$4.33M |
|
300
McKesson
MCK
$102B
| $34.5M | 0.07% |
176,860
+600
| +0.3% | +$110K |
|
Similar funds
Adage Capital Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Adage Capital Partners held 1,104 positions worth $49B, up 6.8% from $45.9B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Adage Capital Partners's Q1 2021 filing shows 303 new, 294 increased, 324 reduced and 153 closed positions. Its largest new stake was GW Pharmaceuticals Plc American Depositary Shares: 1,500,000 shares worth $325M. The largest sale was Royalty Pharma, an estimated $665M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 21% a quarter earlier, followed by Healthcare and Financials.
- Adage Capital Partners's largest Q1 2021 buy was GW Pharmaceuticals Plc American Depositary Shares: 1,500,000 shares worth $325M.
- Adage Capital Partners added most to Alexion Pharmaceuticals in Q1 2021, an estimated $205M increase.
- Adage Capital Partners's biggest Q1 2021 reduction was Royalty Pharma, cutting an estimated $665M.
- Adage Capital Partners fully exited CONCHO RESOURCES INC. in Q1 2021, selling an estimated $175M.
- Adage Capital Partners's ten largest holdings make up 21% of its $49B portfolio in Q1 2021.
- Adage Capital Partners opened 303 new positions and closed 153 in Q1 2021.
- Adage Capital Partners's portfolio value rose 6.8% quarter-over-quarter to $49B.
Based on Adage Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.